bemesetron

Subscribe to Selected New Research on bemesetron

29 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: does not block smooth muscle contractile responses elicited by oxytocin or mediated through serotonin D-receptors, muscarinic or nicotinic cholinoreceptors or histamine H1-receptors except at relatively high concentrations; MDL 72699 is quaternary salt of MDL 72222

Also Known As:

1 alphaH,3 alphaH,5 alphaH-tropan-3-yl-3,5-dichlorobenzoate; MDL 72222; MDL 72699; MDL-72222; MDL-72699

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Heterocyclic Compounds: 23

Alkaloids: 633

Tropanes: 1

bemesetron: 29

Bridged-Ring Heterocyclic Compounds

Tropanes: 1

bemesetron: 29

Polycyclic Compounds: 58

Bridged Compounds: 2

Bicyclo Compounds

Heterocyclic Bicyclo Compounds

Azabicyclo Compounds

Tropanes: 1

bemesetron: 29

Related Diseases

1.	Vomiting 01/01/1993 - "5. A 5-hydroxytryptamine3 (5-HT3) receptor antagonist, MDL 72222 (1 mg kg-1), reduced emesis when given alone and combined with metoclopramide (low dose)" 02/01/1992 - "PBG-induced vomiting was blocked by the 5-HT3 receptor antagonist MDL 72222" 11/01/1995 - "MDL 72222 blocked ipecac-induced vomiting in a dose-related manner and was partially effective in attenuating cisplatin-induced emesis" 05/12/1994 - "On the other hand, blocking 5-HT3 receptors with MDL 72222 (0.5 and 5 mg/kg, i.v.) or low doses (0.01 mg/kg i.v.) of ICS 205-930 had no apparent effect on the vomiting induced by copper sulfate" 07/01/1986 - "MDL 72222, the selective 5-hydroxytryptamine (5-HT) M-receptor antagonist, prevented or reduced cisplatin-induced emesis in ferrets" Get all the results and reference details, order at left...
2.	Catalepsy 01/01/1995 - "Bemesetron significantly reduced catalepsy at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect" 01/01/1995 - "The aim of this study was to examine the effects of bemesetron and granisetron, two selective 5-HT3 receptor antagonists, on this catalepsy in mice" Get all the results and reference details, order at left...
3.	Bradycardia 07/01/1990 - "MDL 72222 had no effect on the bradycardia associated with embolization; however, it significantly reduced the decrease in arterial blood pressure and converted the decrease in tidal volume seen in pulmonary embolism to an increase" 07/14/1988 - "The bradycardia was unaffected by the 5-HT3 antagonist, MDL 72222, but was reversed by atropine and was abolished in bi-vagotomised cats" 06/01/1987 - "In the absence of MDL 72222 the reflex bradycardia partially concealed a positive chronotropic response to 5-HT" 09/01/1986 - "Treatment with MDL 72222, 0.3 mg/kg i.v., abolished the initial depressor response and bradycardia produced by 5-HT" 08/01/1985 - "Administration of MDL 72222, a selective antagonist of M-type 5-HT receptors, blocked bradycardia elicited by 5-HT without affecting that caused by stimulation of the vagus nerve" Get all the results and reference details, order at left...
4.	Tachycardia (Tachyarrhythmias) 09/01/1994 - "4. The tachycardia was not affected by MDL 72222, metoclopramide and cocaine" 05/01/1998 - "Two 5-HT3 receptor antagonists (ondansetron and MDL-72222) blocked hypotension and restored tachycardia, basic features of orthostatic adaptation of the circulatory system" 01/01/1989 - "In contrast, atenolol antagonized this tachycardia and the 5-HT antagonists methysergide, ketanserin and MDL 72222 reduced it" 06/01/1987 - "After blockade of the bradycardia response by MDL 72222, 5-HT elicited a significant tachycardia, which was not altered by propranolol and phentolamine, but was prevented by phenoxybenzamine" 01/01/1992 - "The 5-HT1 receptor antagonists, pindolol and spiroxatrine, the 5-HT3 receptor antagonist MDL 72222 and the alpha 2-adrenoceptor blocking agent idazoxan failed to antagonize the tachycardia induced by 5-HT" Get all the results and reference details, order at left...
5.	Pain (Aches) 04/01/1989 - "However, ICS-205-930, MDL-72222 and GR-38032F all produced dose-dependent analgesia in the chemical pain test, that was not altered by systemic naloxone administration (1 mg/kg, s.c.)" 10/24/1989 - "Intraplantar administration of serotonin 5-HT3 receptor antagonists ICS 205-930 and MDL 72222 (1-100 micrograms; 50 microliters) produced dose-related analgesia against formalin-induced acute- and Freunds adjuvant-induced chronic-inflammatory pain in rats" Get all the results and reference details, order at left...
14 Diseases and 29 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Ipecac (Syrup of Ipecac)
3.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
4.	Granisetron (Kytril)
5.	Serotonin (5 Hydroxytryptamine)
6.	tropisetron (Navoban)
7.	Ondansetron (Zofran)
8.	Ketanserin
9.	Propranolol (Inderal)
10.	Metoclopramide (Reglan)
40 Drugs and Important Bio-Agents and 29 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Analgesia
2.	Induced Hyperthermia (Thermotherapy)
3.	Drug Therapy (Chemotherapy)
3 Therapies and Procedures and 4 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>